Lilly's Competitive Clinical Research Grant
Lilly's Competitive Clinical Research Grant from Eli Lilly and Company funds independent studies on mirkizumab’s real-world effectiveness and IBD epidemiology in Canada.
Funder: Eli Lilly and Company
Due Dates (Anticipated): June 2027 (Full application/submission deadline)
Funding Amounts: Funding and/or study drug support; award size and duration vary by proposal and are specified in each RFP.
Summary: Supports independent, externally led clinical research on mirkizumab in IBD, with a focus on real-world effectiveness and epidemiology in Canada.
Key Information: This is a forecasted opportunity; timelines and details may shift—monitor the program page for updates.
Description
Lilly's Competitive Clinical Research Grant, managed by Eli Lilly and Company, invites external researchers to propose studies that are initiated, designed, and sponsored outside of Lilly. The program operates through publicly posted Requests for Proposals (RFPs) that outline specific scientific priorities and submission timelines. For the Canada mirkizumab IBD RFP, the focus is on real-world effectiveness studies and disease-state epidemiology in overweight or obese individuals living with IBD in Canada. Proposals are reviewed by global committees of Lilly scientific and medical experts, and sometimes external reviewers. Approved projects are conducted independently by the grantee, who retains full responsibility for study design, conduct, and regulatory compliance.
